SEC Form 4 · accession 0001213900-18-008296
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Napoleone Ferrara
Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 7:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $0.70 | Jun 22, 2018 | A | 54,514 | A | — | Jun 22, 2028 | Common Stock | 54,514 | 54,514 | D |
| Performance Stock UnitsF2 | — | Jun 22, 2018 | A | 200,000 | A | — | Jul 7, 2022 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1One-third of the award vests on May 31, 2019, the remainder of the award vests in equal installments each three months thereafter, commencing on August 31, 2019
- F2Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance.